ACG 2026 - Med Pharma News

Graphic: TissueCypher Barrett's esophagus test pathway from biopsy to risk class to management plan, with 83% low risk and 96% matched recommendations

Castle Biosciences Data Show Barrett’s Risk Test Shifts Surveillance Plans

Megan Wood2 hours ago2 hours ago012 mins

Castle Biosciences says TissueCypher changed Barrett’s management for 96% of cohort patients. Where the test fits in surveillance and what is unproven.